Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly AmBisome maintenance therapy for invasive fungal infection in AML or allogeneic HSCT patients
2011-001845-34Phase 2Completed
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amphotericin b in invasive mycoses and aspergillosis, sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoint: Overall response at 10 weeks from start of maintenance therapy. Started Mar 2012; status: completed.
02
Drugs
amphotericin b
03
Conditions
invasive mycosesaspergillosis
Beyond the preview
Go deeper on 2011-001845-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001845-34.